How to buy HUTCHMED China stock | $32.06

HUTCHMED (China) Limited is a biotechnology business based in the US. HUTCHMED China shares (HCM) are listed on the NASDAQ and all prices are listed in US Dollars. HUTCHMED China employs 1,280 staff and has a trailing 12-month revenue of around 0.00.

HUTCHMED China stock price (NASDAQ: HCM)

Use our graph to track the performance of HCM stocks over time.

HUTCHMED China shares at a glance

• Key figures

Information last updated 2021-10-25.

Latest market close	$32.06
52-week range	$23.67 - $43.94
50-day moving average	$35.55
200-day moving average	$34.16
Wall St. target price	$46.57
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.24

Buy HUTCHMED China shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy HUTCHMED China stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

HUTCHMED China price performance over time

Historical closes compared with the close of $32.06 from 2021-10-25

1 week (2021-10-19)	-0.62%
1 month (2021-09-27)	-14.05%
3 months (2021-07-27)	-12.04%
6 months (2021-04-27)	6.90%

1 year (2020-10-26)	6.69%
2 years (2019-10-25)	59.82%
3 years (2018-10-26)	8.27%
5 years (2016-10-26)	172.62%

HUTCHMED China financials

Revenue TTM	$278.6 million
Gross profit TTM	$-135,319,000
Return on assets TTM	-18.23%
Return on equity TTM	-24.13%
Profit margin	-64.05%
Book value	$5.86
Market capitalisation	$5.7 billion

TTM: trailing 12 months

Shorting HUTCHMED China shares

There are currently 1.8 million HUTCHMED China shares held short by investors – that's known as HUTCHMED China's "short interest". This figure is 3.6% down from 1.8 million last month.

There are a few different ways that this level of interest in shorting HUTCHMED China shares can be evaluated.

HUTCHMED China's "short interest ratio" (SIR)

HUTCHMED China's "short interest ratio" (SIR) is the quantity of HUTCHMED China shares currently shorted divided by the average quantity of HUTCHMED China shares traded daily (recently around 195286.66666667). HUTCHMED China's SIR currently stands at 9. In other words for every 100,000 HUTCHMED China shares traded daily on the market, roughly 9000 shares are currently held short.

However HUTCHMED China's short interest can also be evaluated against the total number of HUTCHMED China shares, or, against the total number of tradable HUTCHMED China shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case HUTCHMED China's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 HUTCHMED China shares in existence, roughly 10 shares are currently held short) or 0.019% of the tradable shares (for every 100,000 tradable HUTCHMED China shares, roughly 19 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against HUTCHMED China.

Find out more about how you can short HUTCHMED China stock.

HUTCHMED China share dividends

We're not expecting HUTCHMED China to pay a dividend over the next 12 months.

Have HUTCHMED China's shares ever split?

HUTCHMED China's shares were split on a 10:1 basis on 29 May 2019. So if you had owned 1 share the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your HUTCHMED China shares – just the quantity. However, indirectly, the new 90% lower share price could have impacted the market appetite for HUTCHMED China shares which in turn could have impacted HUTCHMED China's share price.

HUTCHMED China share price volatility

Over the last 12 months, HUTCHMED China's shares have ranged in value from as little as $23.67 up to $43.94. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while HUTCHMED China's is 0.6657. This would suggest that HUTCHMED China's shares are less volatile than average (for this exchange).

HUTCHMED China overview

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co.

Frequently asked questions

What percentage of HUTCHMED China is owned by insiders or institutions?
Currently 1.414% of HUTCHMED China shares are held by insiders and 28.808% by institutions. How many people work for HUTCHMED China?
Latest data suggests 1,280 work at HUTCHMED China. When does the fiscal year end for HUTCHMED China?
HUTCHMED China's fiscal year ends in December. Where is HUTCHMED China based?
HUTCHMED China's address is: Cheung Kong Center, Central, Hong Kong What is HUTCHMED China's ISIN number?
HUTCHMED China's international securities identification number is: US44842L1035 What is HUTCHMED China's CUSIP number?
HUTCHMED China's Committee on Uniform Securities Identification Procedures number is: 44842L103